Greenleaf Trust Sells 485 Shares of Moderna, Inc. (NASDAQ:MRNA)

Greenleaf Trust reduced its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 17.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,300 shares of the company’s stock after selling 485 shares during the period. Greenleaf Trust’s holdings in Moderna were worth $229,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of MRNA. The Manufacturers Life Insurance Company raised its holdings in Moderna by 77.3% during the third quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock valued at $400,367,000 after buying an additional 1,690,341 shares in the last quarter. Invesco Ltd. increased its stake in shares of Moderna by 19.8% in the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock worth $322,887,000 after purchasing an additional 517,683 shares during the period. Wellington Management Group LLP lifted its position in shares of Moderna by 9.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock worth $579,572,000 after purchasing an additional 476,201 shares during the last quarter. Bamco Inc. NY lifted its position in shares of Moderna by 4,863.6% during the 3rd quarter. Bamco Inc. NY now owns 426,869 shares of the company’s stock worth $44,091,000 after purchasing an additional 418,269 shares during the last quarter. Finally, International Assets Investment Management LLC lifted its position in shares of Moderna by 6,528.9% during the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock worth $38,552,000 after purchasing an additional 381,808 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $108.85 on Thursday. The business has a fifty day moving average of $101.85 and a two-hundred day moving average of $93.64. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $142.79. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.53 billion. During the same period last year, the company posted $3.61 earnings per share. The firm’s quarterly revenue was down 44.9% compared to the same quarter last year. As a group, research analysts forecast that Moderna, Inc. will post -7.51 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on MRNA. HSBC reissued a “reduce” rating and issued a $86.00 price objective (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 target price on shares of Moderna in a research report on Tuesday, April 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $125.00 target price on shares of Moderna in a research report on Thursday, March 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. Finally, Oppenheimer raised Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price for the company in a research report on Tuesday, January 2nd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus target price of $126.49.

Insider Activity

In other news, CFO James M. Mock sold 647 shares of the firm’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares in the company, valued at $406,651. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $108.54, for a total value of $1,628,100.00. Following the completion of the sale, the director now directly owns 2,131,931 shares in the company, valued at $231,399,790.74. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO James M. Mock sold 647 shares of Moderna stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the sale, the chief financial officer now owns 4,300 shares of the company’s stock, valued at $406,651. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 109,954 shares of company stock worth $11,533,976. 15.70% of the stock is owned by corporate insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.